Patents by Inventor Rima Jaber

Rima Jaber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing nanoparticles in the form of a powder comprising a bio-resorbable polyester
    Patent number: 11964058
    Abstract: A process can be used for preparing nanoparticles containing at least one bio-resorbable polyester. The nanoparticles are in the form of a powder with a Z-Average particle size Dz in the range of 1 to 450 nm, and with a polydispersity index PDI in the range of 0.01 to 0.5. The process involves emulsion-solvent extraction or emulsion-solvent evaporation, and application of ultrasonic sound.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: April 23, 2024
    Assignee: Evonik Corporation
    Inventors: David Fecher, Maria Camilla Operti, Rima Jaber, Andrea Engel, Silko Grimm, Min Yang
  • ENZYME BASED PRODUCTION OF SPECIALIZED PRO-RESOLVING MEDIATORS (SPMS) VIA DOCOSAHEXAENOIC ACID (DHA) AND EICOSAPENTAENOIC ACID (EPA)
    Publication number: 20240026394
    Abstract: The present invention refers to a method for producing hydroxylated fatty acids by oxidizing at least one unsaturated fatty acid by at least one lipoxygenase and thereafter reducing the obtained compound by at least one peroxidase and/or heating. Furthermore, the present invention refers to the compound obtained by said method.
    Type: Application
    Filed: November 19, 2021
    Publication date: January 25, 2024
    Applicant: Evonik Operations GmbH
    Inventors: Rima JABER, Katharina BERSE, Eva Maria WITTMANN
  • Process for preparing nanoparticles in the form of a powder comprising a bio-resorbable polyester
    Publication number: 20220354803
    Abstract: A process can be used for preparing nanoparticles containing at least one bio-resorbable polyester. The nanoparticles are in the form of a powder with a Z-Average particle size D, in the range of 3 to 450 nm, and with a polydispersity index PDI in the range of 0.01 to 0.5. The process involves emulsion-solvent extraction or emulsion-solvent evaporation, and application of ultrasonic sound.
    Type: Application
    Filed: September 25, 2020
    Publication date: November 10, 2022
    Applicant: EVONIK CORPORATION
    Inventors: David Fecher, Maria Camilla Operti, Rima Jaber, Andrea Engel, Silko Grimm, Min Yang
  • INJECTION SOLUTION COMPRISING A NON-NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR AND POLY(LACTIDE-CO-GLYCOLIDE)
    Publication number: 20190343762
    Abstract: An injection solution contains an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent and a pharmaceutical active ingredient which is non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups. The content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.
    Type: Application
    Filed: July 25, 2019
    Publication date: November 14, 2019
    Applicant: Evonik Roehm GmbH
    Inventors: Norbert WINDHAB, Rima Jaber, Axel Schroeder, Kevin Burton, Tom Tice
  • Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)
    Patent number: 10406098
    Abstract: An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: September 10, 2019
    Assignee: Evonik Roehm GmbH
    Inventors: Norbert Windhab, Rima Jaber, Axel Schroeder, Kevin Burton, Tom Tice
  • INJECTION SOLUTION COMPRISING A NON-NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR AND POLY(LACTIDE-CO-GLYCOLIDE)
    Publication number: 20180318211
    Abstract: An injection solution can be used in a pharmaceutical dosage formulation. The injection solution includes an organic solvent, a copolymer, which is a poly(lactide-co-glycolide) dissolved in the organic solvent, and a pharmaceutical active ingredient, which is a non-nucleoside inhibitor of the HIV reverse transcriptase or of the HIV integrase, and which contains aromatic and heterocyclic aromatic or aromatic and heterocyclic aromatic and aliphatic heterocyclic groups, where a content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.
    Type: Application
    Filed: November 11, 2016
    Publication date: November 8, 2018
    Applicant: Evonik Roehm GmbH
    Inventors: Norbert Windhab, Rima Jaber, Axel Schroeder, Kevin Burton, Tom Tice